Oncopeptides to present melflufen HORIZON subgroup poster at IMS Glasgow
The analysis stratifies relapsed refractory myeloma patients by prior anti-CD38 antibody exposure, which the company calls hypothesis-generating on treatment sequencing.
TR
By Tom Reyes · Markets Editor
Sep 21 11:00 ETSource: TradingView
The wire
- 01Oncopeptides will attend the 23rd International Myeloma Society meeting in Glasgow, September 23-26, 2026, with an accepted poster on melflufen plus dexamethasone in the OP-106 HORIZON study.
- 02Pepaxti (melflufen) is a peptide-drug conjugate commercialized in Europe, and the company says it has expanded its PDC platform into new indications including glioblastoma.
- 03The poster is a retrospective subgroup analysis the company itself describes as hypothesis-generating, not a new controlled readout.
From the source
Read at tradingview.comOncopeptides to highlight clinical progress and present new data at the IMS Annual Meeting
STOCKHOLM – September 21, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces its participation in the 23rd International Myeloma Society (IMS) Annual Meeting, taking place in Glasgow, Scotland, from September 23–26, 2026.